Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dense Deposit Disease”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Early research (Phase 1)Study completedNCT01221181
What this trial is testing

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Who this might be right for
Dense Deposit DiseaseMembranoproliferative Glomerulonephritis
Columbia University 6
Early research (Phase 1)Ended earlyNCT01791686
What this trial is testing

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

Who this might be right for
Dense Deposit DiseaseMembranoproliferative Glomerulonephritis Type IIC3 Glomerulonephritis
Celldex Therapeutics 1
Large-scale testing (Phase 3)Looking for participantsNCT03955445
What this trial is testing

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Who this might be right for
C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)UnknownNCT02682407
What this trial is testing

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Who this might be right for
IgANLupus NephritisMN+1 more
Omeros Corporation 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT04572854
What this trial is testing

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Who this might be right for
C3GIC-MPGNRenal Transplant+9 more
Apellis Pharmaceuticals, Inc. 13
Not applicableApproved For MarketingNCT04729062
What this trial is testing

C3G/Primary IC-MPGN EAP

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Early research (Phase 1)WithdrawnNCT02302755
What this trial is testing

TP10 Use in Patients With C3 Glomerulopathy (C3G)

Who this might be right for
Dense Deposit Disease
University of Iowa
Not applicableStudy completedNCT03723512
What this trial is testing

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Mario Negri Institute for Pharmacological Research 7
Testing effectiveness (Phase 2)Looking for participantsNCT04183101
What this trial is testing

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Who this might be right for
C3 GlomerulopathyMembranoproliferative GlomerulonephritisComplement Abnormality+2 more
Region Skane 30
Early research (Phase 1)WithdrawnNCT00583427
What this trial is testing

Sulodexide Treatment in Patients With Dense Deposit Disease

Who this might be right for
Dense Deposit Disease
University of Iowa
Testing effectiveness (Phase 2)Study completedNCT03301467
What this trial is testing

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Who this might be right for
C3 Glomerulopathy (C3G)
Amgen 57
Testing effectiveness (Phase 2)Study completedNCT03369236
What this trial is testing

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Who this might be right for
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Alexion Pharmaceuticals, Inc. 13
Large-scale testing (Phase 3)Active Not RecruitingNCT05809531
What this trial is testing

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 100
Testing effectiveness (Phase 2)Study completedNCT03124368
What this trial is testing

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Who this might be right for
C3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more
Alexion Pharmaceuticals, Inc. 6
Large-scale testing (Phase 3)Study completedNCT05067127
What this trial is testing

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 124
Testing effectiveness (Phase 2)Study completedNCT03453619
What this trial is testing

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Who this might be right for
IgA NephropathyLupus NephritisMembranous Nephropathy+2 more
Apellis Pharmaceuticals, Inc. 21
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000